Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71.
• On Wednesday, June 3rd, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.07, for a total transaction of $690,700.00.
• On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00.

Halozyme Therapeutics Stock Up 2.6%

Shares of NASDAQ HALO opened at $107.62 on Thursday. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The company has a 50 day simple moving average of $81.71 and a 200 day simple moving average of $73.26. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $107.96. The firm has a market cap of $12.21 billion, a PE ratio of 32.13, a price-to-earnings-growth ratio of 0.42 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period in the prior year, the business posted $1.54 earnings per share. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on HALO shares. Wells Fargo & Company lifted their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. UBS Group reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. TD Cowen upped their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, HC Wainwright raised their price target on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Institutional Trading of Halozyme Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Two Sigma Securities LLC purchased a new stake in shares of Halozyme Therapeutics in the second quarter worth $980,000. Cookson Peirce & Co. Inc. purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter worth $486,000. Royal London Asset Management Ltd. increased its position in shares of Halozyme Therapeutics by 12.4% during the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock valued at $141,732,000 after purchasing an additional 200,262 shares during the last quarter. Hsbc Holdings PLC boosted its stake in shares of Halozyme Therapeutics by 452.1% during the 2nd quarter. Hsbc Holdings PLC now owns 158,889 shares of the biopharmaceutical company’s stock worth $12,447,000 after acquiring an additional 130,108 shares during the last quarter. Finally, Archer Investment Corp bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $78,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.